Physician profile
Benjamin William West
NPI 1376587220
$1,451.48
in general payments reported to CMS, 2019-2025
33 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.22 · 2022: $28.36 · 2023: $128 · 2024: $236 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $190.59 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Daiichi Sankyo INC. | $175.55 | 2024-2025 | Enhertu |
| Tempus Ai, INC | $101.06 | 2024 | |
| Glaxosmithkline, LLC. | $99.26 | 2023-2025 | Ojjaara, Zejula, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $76.68 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Karyopharm Therapeutics INC. | $67.50 | 2024-2025 | Xpovio |
| Lilly USA, LLC | $66.93 | 2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $66.53 | 2025 | Keytruda |
| Genentech USA, INC. | $51.94 | 2025 | Itovebi |
| Astellas Pharma US INC | $43.27 | 2025 | Vyloy, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $37.19 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $36.98 | 2025 | Onivyde |
| Pfizer INC. | $36.71 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $34.46 | 2024-2025 | Libtayo |
| Genzyme Corporation | $31.42 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $29.18 | 2025 | Epkinly |
| Eisai INC. | $24.23 | 2025 | |
| Array Biopharma INC | $23.25 | 2025 | Mektovi, Braftovi, Lorbrena |
| Syndax Pharmaceuticals, INC. | $22.70 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.62 | 2025 | |
| Sirtex Medical INC | $21.28 | 2023 | Sir-Spheres Microspheres |
| Pharmaessentia USA Corporation | $19.63 | 2025 | Besremi |
| Myriad Genetic Laboratories, INC. | $18.03 | 2025 | Prolaris |
| Geron Corporation | $17.76 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $17.44 | 2025 | Ultomiris |
| Beone Medicines USA, INC. | $17.43 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $15.83 | 2023 | Ayvakit |
| Tersera Therapeutics LLC | $15.82 | 2025 | Zoladex |
| Emd Serono, INC. | $14.87 | 2023 | Bavencio |
| Caris Mpi, INC. | $14.68 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $14.67 | 2025 | |
| Rigel Pharmaceuticals, INC. | $13.92 | 2023 | Tavalisse, Rezlidhia |
| Epizyme, INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.